

Mouse Anti-PD-L1/PDCD1-L1/CD274 [PDL1/2746]: MC0300, MC0300RTU7

Intended Use: For Research Use Only

Description: Programmed cell death ligand 1 (PD-L1) also known as CD274 or B7-H1, a member of the B7 family of cell surface ligands, involved in regulation of T cell activation and humoral immune responses. PD-1 is expressed on tumor-infiltrating lymphocytes (TIL) while PD-L1 is expressed on tumor cells including melanoma, diffused large B-cell lymphoma, lung, ovary, colon, breast, rectum and renal cell carcinomas. B7.1 is a molecule expressed on antigen presenting cells and activated T cells. PD-L1 binding to B7.1 on T cells and antigen presenting cells can mediate down-regulation of immune responses, including inhibition of T-cell activation and cytokine production. PD-L1 binding to its transmembrane inhibitory receptor PD-1 provides both stimulatory and inhibitory signals in regulating T cell activation and tolerance during pregnancy, tissue allografts, autoimmune disease and malignant transformation. Therefore, blocking the PD1/PD-L1 immune inhibitory checkpoints represents an attractive strategy to reinvigorate tumor-specific T cell immunity suppressed by the expression of PD-L1 in the tumor microenvironment. Detection of PD-L1 overexpression by IHC can be useful to identify tumors and support meaningful benefit for patients.

Specifications:


Clone:	PDL1/2746
Source:	Mouse
Isotype:	IgG2b/k
Reactivity:	Human, mouse
Localization:	Membrane, cytoplasm
Formulation:	Antibody in PBS pH7.4, containing BSA and $\leq 0.09\%$ sodium azide (NaN ₃)
Storage:	Store at 2°- 8°C
Applications:	IHC, ELISA, Flow Cyt., IF, WB
Package:	

Description	Catalog No.	Size
PD-L1/PDCD1-L1/CD274 Concentrated	MC0300	1 ml
PD-L1/PDCD1-L1/CD274 Prediluted	MC0300RTU7	7 ml

IHC Procedure*:

Positive Control Tissue:	Lung cancer, placenta
Concentrated Dilution:	50-200
Pretreatment:	Citrate pH6.0 or EDTA pH8.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C
Incubation Time and Temp:	30-60 minutes @ RT
Detection:	Refer to the detection system manual

* Result should be confirmed by an established diagnostic procedure.



FFPE human breast carcinoma stained with anti-PD-L1 using DAB

References:

1. Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. Lastwika, K. J., et al. Cancer Research, 15 January 2016.
2. UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. Wong, S. Q., et al..Cancer Research, 15 December 2015.
3. PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. Mahoney, K. M., et al. Cancer Immunology Research, 1 December 2015.

Doc. 100-MC0300
Rev. A